# China Insulin Market Size, Share & Forecast, By Insulin Type, Diabetes Type & Distribution Channel, 2025-2032 --- ## Market Overview # CHAPTER 1 - Market Overview The China Insulin Market serves a structurally large diabetes population, with approximately **148 million adults living with diabetes in 2024**. Around **10 million patients use insulin**, creating a recurring pharmaceutical demand pool across type 1 diabetes and insulin-requiring type 2 diabetes. Commercial performance therefore depends on treatment initiation, persistence, dose intensity and mix rather than diabetes prevalence alone. East and Coastal China represents the strongest commercial concentration in the report's geographic framework, reflecting dense tertiary-care networks, pharmaceutical manufacturing clusters and large urban diabetes populations. Distribution itself is national: more than **35,000 medical institutions** submitted demand exceeding **240 million insulin units** in the 2024 continuation procurement, giving leading suppliers broad institutional reach rather than dependence on one metropolitan market. Pricing is structurally governed by centralized volume-based procurement. The first national insulin procurement reduced selected-product prices by approximately **48%**, with implementation beginning in 2022. The 2024 continuation procurement maintained broadly stable tender prices while delivering a further **3.8 percentage-point reduction** across selected products. This limits pricing-led growth but improves affordability, treatment access and contracted-volume visibility. The strategic direction is toward higher-quality insulin mix and stronger domestic participation. Third-generation insulin usage increased from **58% before centralized procurement to 70% afterward**. Separately, domestic products represented approximately **45% of hospital-reported procurement demand** in the 2024 continuation round, roughly 14 percentage points above the first round, creating a sustained localization and portfolio-upgrading opportunity. ## KPIs at a Glance * Market Value: USD 2,950 million (2025) * Dominant Region: East and Coastal China * Dominant Segment: Insulin Analogs (fastest growing) * Total Number of Players: 13 ## Future Outlook The China Insulin Market is projected to expand from **USD 2,950 million in 2025** to **USD 3,883 million by 2032**, representing a **4.00% CAGR during 2025-2032**. The forecast represents a normalization phase following the sharp procurement-led repricing that reduced market value from its 2020 peak. Historical market value therefore records a **-7.54% CAGR during 2020-2025**, even as treated volume increased. Future value creation is expected to rely on higher insulin utilization, continuing migration toward analog formulations, once-weekly basal innovation and gradual domestic manufacturer share gains rather than restoration of pre-procurement pricing. Volume is expected to expand faster than market value as centralized procurement continues to restrain realized price per unit. The modeled annual insulin volume rises from approximately **365 million units in 2025** to about **520 million units by 2032**, while the blended realized value per unit gradually declines. This creates a scale-oriented operating environment in which manufacturing efficiency, tender positioning, formulation mix and hospital access are decisive. Long-acting, ultra-long and convenient pen-based formulations should capture a rising share of value, while GLP-1 and GIP/GLP-1 therapies create substitution pressure in selected type 2 diabetes cohorts. --- | | | | --- | --- | | **4.00%** Forecast CAGR (2025-2032) | **$3,883 Mn** 2032 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2025-2032** | Historical CAGR **-7.54%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** China * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2025-2032 (base year inclusive) * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Care Setting, End User, Disease Area, Channel, Technology, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn/Bn ### Segmentation Data Tree * Product Type + Human Insulin - Regular Human Insulin - NPH Human Insulin + Rapid-Acting Insulin Analogs - Insulin Aspart - Insulin Lispro + Long-Acting and Ultra-Long Analogs - Insulin Glargine - Degludec and Icodec Formulations + Premixed Insulin - Human Premixed Insulin - Analog Premixed Insulin * Care Setting + Tertiary Hospitals - Endocrinology Departments - Multidisciplinary Diabetes Centers + Secondary Hospitals - Municipal Hospitals - County Hospitals + Primary and Community Care - Community Health Centers - Township Health Centers + Specialist Diabetes Clinics - Public Outpatient Diabetes Clinics - Private Specialty Clinics * End User + Adult Patients - Insulin-Naive Adults - Established Insulin Users + Geriatric Patients - Multimorbid Patients - High Hypoglycemia-Risk Patients + Pediatric and Adolescent Patients - School-Age Patients - Adolescent Patients * Disease Area + Type 1 Diabetes - Newly Diagnosed Type 1 Diabetes - Long-Duration Type 1 Diabetes + Type 2 Diabetes - Basal Insulin Initiation - Basal-Bolus Intensification + Gestational Diabetes - Pregnancy-Diagnosed Diabetes - Pre-Existing Diabetes in Pregnancy + Secondary and Other Diabetes - Pancreatic Disease-Related Diabetes - Steroid-Induced Diabetes * Channel + Public Hospital Pharmacies - Centralized Procurement Products - Hospital Formulary Supply + Private Hospital and Clinic Pharmacies - Direct Institutional Supply - Specialist Clinic Dispensing + Retail Pharmacies - National and Regional Chains - Independent Pharmacies + Digital and Online Pharmacies - O2O Pharmacy Fulfillment - E-Prescription Home Delivery * Technology + Vial and Syringe Formulations - Standard Multi-Dose Vials - Institutional Vial Formats + Reusable Pen Cartridges - 3 mL Cartridges - Proprietary Reusable Pen Systems + Prefilled Disposable Pens - Basal Analog Pens - Rapid and Premix Analog Pens + Pump-Compatible Insulin Formulations - Rapid-Acting Pump Insulin - Reservoir-Compatible Formulations * Geography + East and Coastal China - Yangtze River Delta - Major Eastern Coastal Provinces + North and Northeast China - Beijing-Tianjin-Hebei - Northeast Provinces + Central and South China - Central Provincial Markets - Southern Metropolitan Clusters + West China - Southwest Provinces - Northwest Provinces --- ## Market Trajectory # China Insulin Market Size, Share & Forecast, By Insulin Type, Diabetes Type & Distribution Channel, 2025-2032 **Geography:** China | **Study Period:** 2020-2032 | **Base Year:** 2025 | **Forecast Period:** 2025-2032 The China Insulin Market is estimated at **USD 2,950 million in 2025**. Structural demand is supported by approximately **148 million adults living with diabetes in China in 2024** and around **10 million people using insulin**. Following the national procurement price reset, market economics are shifting from price-led value expansion toward higher treatment volumes, insulin analog mix upgrading and increasing domestic manufacturer participation. ## Report Metadata Summary | | | | --- | --- | | **Base Year** | 2025 | | **CAGR for Past 5 Years** | -7.54% | | **Historical Period** | 2020-2025 | | **Forecast Period** | 2025-2032 | | **Forecast Period CAGR** | 4.00% | # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. ### Historical and Projected Market Size (USD Mn) | Year | Market Size (USD Mn) | Status | | --- | --- | --- | | 2020 | 4,365 | Historical | | 2021 | 4,280 | Historical | | 2022 | 3,560 | Historical | | 2023 | 2,710 | Historical | | 2024 | 2,837 | Historical | | 2025 | 2,950 | Base Year | | 2026F | 3,068 | Forecast | | 2027F | 3,191 | Forecast | | 2028F | 3,319 | Forecast | | 2029F | 3,452 | Forecast | | 2030F | 3,590 | Forecast | | 2031F | 3,733 | Forecast | | 2032F | 3,883 | Forecast | ### YoY Growth Rate (%) | Year | YoY Growth (%) | | --- | --- | | 2021 | -1.9% | | 2022 | -16.8% | | 2023 | -23.9% | | 2024 | 4.7% | | 2025 | 4.0% | | 2026F | 4.0% | | 2027F | 4.0% | | 2028F | 4.0% | | 2029F | 4.0% | | 2030F | 4.0% | | 2031F | 4.0% | | 2032F | 4.0% | ### Market Value vs Volume Growth (%) | Year | Market Value Growth (%) | Insulin Volume Growth (%) | | --- | --- | --- | | 2020 | - | - | | 2021 | -1.9% | 2.0% | | 2022 | -16.8% | 13.7% | | 2023 | -23.9% | 17.2% | | 2024 | 4.7% | 2.9% | | 2025 | 4.0% | 4.3% | | 2026 | 4.0% | 5.5% | | 2027 | 4.0% | 5.2% | | 2028 | 4.0% | 5.2% | | 2029 | 4.0% | 5.2% | | 2030 | 4.0% | 5.1% | | 2031 | 4.0% | 5.1% | | 2032 | 4.0% | 5.1% | ### Historical Market Performance (2020-2025) The historical period is defined by a major price-led structural reset rather than a contraction in clinical need. The modeled 2020 market peak of USD 4,365 million fell sharply as centralized procurement repriced major insulin products, reaching a trough of USD 2,710 million in 2023. By 2024, market value recovered to USD 2,837 million as higher treatment volumes, analog migration and improved hospital access began offsetting lower realized prices. The 2025 base value of USD 2,950 million therefore represents the normalization of post-procurement economics rather than a return to pre-procurement price levels. ### Forecast Market Outlook (2025-2032) The forecast assumes a stable post-reset pricing structure with value expansion driven primarily by unit growth and product mix. Market value reaches USD 3,883 million by 2032 at a 4.00% CAGR. Modeled insulin volume increases faster than value, reaching approximately 520 million annual units by 2032, reflecting improved access and treatment persistence. Rising analog penetration, once-weekly basal formulations and domestic supplier scaling support revenue growth, while centralized procurement and GLP-1 substitution limit upside. The result is a moderate value-growth market with substantially stronger underlying pharmaceutical consumption than the historical value series alone suggests. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The China Insulin Market has transitioned from a high-price, multinational-led structure toward a higher-volume procurement market. For CEOs and investors, the decisive metrics are now treated volume, insulin analog mix and domestic manufacturer participation rather than headline list-price expansion. | Year | Market Size (USD Mn) | YoY Growth (%) | Annual Insulin Units (Mn) | Insulin Analog Share (%) | Domestic Manufacturer Value Share (%) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 4,365 | - | 250 | 58% | 15% | Historical | | 2021 | 4,280 | -1.9% | 255 | 59% | 16% | Historical | | 2022 | 3,560 | -16.8% | 290 | 62% | 24% | Historical | | 2023 | 2,710 | -23.9% | 340 | 67% | 34% | Historical | | 2024 | 2,837 | 4.7% | 350 | 70% | 38% | Historical | | 2025 | 2,950 | 4.0% | 365 | 72% | 40% | Base Year | | 2026 | 3,068 | 4.0% | 385 | 74% | 42% | Forecast and Latest Operating KPIs | | 2027 | 3,191 | 4.0% | 405 | 76% | 44% | Forecast and Industry Outlook | | 2028 | 3,319 | 4.0% | 426 | 78% | 46% | Forecast and Industry Outlook | | 2029 | 3,452 | 4.0% | 448 | 80% | 48% | Forecast and Industry Outlook | | 2030 | 3,590 | 4.0% | 471 | 82% | 50% | Forecast and Industry Outlook | | 2031 | 3,733 | 4.0% | 495 | 84% | 52% | Forecast and Industry Outlook | | 2032 | 3,883 | 4.0% | 520 | 86% | 54% | Forecast and Industry Outlook | **KPI 1, Annual Insulin Units:** **approximately 350 million units, post-procurement annualized use**. Public-hospital insulin use increased materially after the first national procurement, while the 2024 continuation tender collected more than 240 million units of declared demand from over 35,000 institutions, supporting a volume-led market outlook. **KPI 2, Insulin Analog Share:** **70% usage share after procurement**. Third-generation insulin usage rose from 58% before national procurement to 70% afterward as price gaps narrowed, demonstrating that affordability reform can accelerate quality and formulation mix upgrades rather than merely transfer volume toward lower-cost legacy products. **KPI 3, Domestic Manufacturer Value Share:** **38% modeled value share in 2024**. Hospital procurement demand provides an even stronger localization signal: domestic-company products represented approximately 45% of reported continuation-procurement demand, around 14 percentage points above the first round, supporting further domestic value-share expansion. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, patient requirements, institutional purchasing and pharmaceutical distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Product Type | **Fastest Growing Segment:** Technology | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Human Insulin; Rapid-Acting Insulin Analogs; Long-Acting and Ultra-Long Analogs; Premixed Insulin | | 2 | Care Setting | Tertiary Hospitals; Secondary Hospitals; Primary and Community Care; Specialist Diabetes Clinics | | 3 | End User | Adult Patients; Geriatric Patients; Pediatric and Adolescent Patients | | 4 | Disease Area | Type 1 Diabetes; Type 2 Diabetes; Gestational Diabetes; Secondary and Other Diabetes | | 5 | Channel | Public Hospital Pharmacies; Private Hospital and Clinic Pharmacies; Retail Pharmacies; Digital and Online Pharmacies | | 6 | Technology | Vial and Syringe Formulations; Reusable Pen Cartridges; Prefilled Disposable Pens; Pump-Compatible Insulin Formulations | | 7 | Geography | East and Coastal China; North and Northeast China; Central and South China; West China | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions provides insight into pharmaceutical mix, care pathways, procurement behavior, patient requirements and access models. **Product Type** - Product type is the central commercial axis because national procurement directly differentiates human insulin, rapid analog, basal analog and premixed categories. Long-acting and ultra-long analogs increasingly shape portfolio economics as treatment quality, dosing convenience and adherence become more important after broad price compression. Human insulin remains relevant where cost sensitivity and institutional procurement dominate purchasing decisions. **Technology** - Technology is the fastest-evolving dimension as reusable cartridges, prefilled pens and once-weekly basal formulations reduce injection burden and improve treatment convenience. The competitive advantage is shifting from simple molecule availability toward dosing frequency, device compatibility, patient usability and manufacturing economics. Pump-compatible rapid formulations also support premium niches among intensively managed type 1 diabetes patients. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis China is the largest insulin pharmaceutical market among the selected Asian peer countries, supported by the world's largest adult diabetes population and a nationwide centralized procurement system. Market value growth is more moderate than in selected faster-growing peers because China has already completed a substantial procurement-led price reset. ### KPI Summary * Focus Country Ranking: **1st among selected peers** * Focus Country Market Size: **USD 2,837 million (2024)** * China CAGR (2025-2032): **4.00%** | Country | Market Size (2024, USD Mn) | CAGR (%) | Adult Diabetes Cases (2024, Mn) | Pricing / Reimbursement Mechanism | | --- | --- | --- | --- | --- | | China | 2,837 | 4.00% | 148.0 | National volume-based procurement and public insurance | | Japan | 1,280 | 3.70% | 9.0 | National Health Insurance price schedule | | India | 769 | 5.63% | 89.8 | Mixed public procurement and private retail | | South Korea | 612 | 6.60% | 5.0 | National Health Insurance reimbursement | | Indonesia | 166 | 4.14% | 20.4 | National health insurance formulary and public procurement | ### Market Position China ranks first in the selected peer set with a 2024 pharmaceutical insulin market of USD 2,837 million and approximately 148 million adults with diabetes, giving it unmatched underlying treatment scale. ### Growth Advantage China's 4.00% base-case growth is above Japan's published 3.7% rate but below faster peer rates reported for India and South Korea, positioning China as a large, moderate-growth market rather than a pure high-growth market. ### Competitive Strengths China combines procurement scale with broad supplier participation: more than 35,000 institutions reported over 240 million units of demand and 49 of 53 submitted products secured selection in the 2024 continuation round. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges, and emerging opportunities across pharmaceutical production, institutional distribution and patient treatment segments. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the China Insulin Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution and patient treatment segments. ## Growth Drivers ### Large Diabetes Population Sustains a Deep Treatment Pool China had approximately **148 million adults with diabetes (2024, China)**, creating the world's largest national pool of potential diabetes treatment demand. * Approximately **10 million people use insulin (2024, China)**, creating a recurring pharmaceutical demand base across type 1 diabetes and insulin-requiring type 2 diabetes. * Public-hospital insulin use increased from approximately **250 million units annually before procurement to about 350 million units annualized afterward (2024, China)**, showing affordability can expand treated volume even when market value is price-constrained. * Third-generation insulin usage increased to **70% after procurement (2024, China)** from 58% previously, shifting revenue pools toward higher-quality analog formulations. ### National Procurement Expands Access and Institutional Reach The first national insulin procurement delivered an average **48% selected-product price reduction (2021 tender, China)**, materially lowering treatment cost and expanding access. * More than **35,000 medical institutions participated (2024, China)**, giving selected manufacturers national access while increasing the importance of tender execution, distribution and supply reliability. * Institutions declared demand exceeding **240 million units (2024, China)**, giving manufacturers substantial contracted-volume visibility across major insulin categories. * The continuation tender selected **49 of 53 submitted products, a 92% selection rate (2024, China)**, supporting broad supply availability while preserving competitive pressure across manufacturers. ### National Diabetes Management Policy Broadens Diagnosis and Treatment National policy targets at least **60% diabetes awareness by 2030 (China)**, expanding the diagnosed population eligible for structured treatment and disease management. * The policy targets at least **70% standardized primary-care management for type 2 diabetes patients by 2030 (China)**, strengthening longitudinal treatment pathways beyond tertiary hospitals. * The diabetes action plan was jointly issued by **14 national departments (2024, China)**, demonstrating cross-agency coordination across healthcare, insurance, technology and public-health implementation. * Policy explicitly supports digital and innovative diabetes-management technologies through **2030 implementation targets (China)**, increasing potential for insulin companies that integrate adherence support, connected care and primary-care education. --- ## Market Challenges ### Centralized Procurement Compresses Price and Revenue Per Unit National insulin procurement created an initial **48% average selected-product price reduction (China)**, permanently lowering the revenue yield available from mature insulin products. * The 2024 continuation round reduced selected prices by another **3.8 percentage points (2024, China)**, limiting the scope for manufacturers to rebuild revenue through price increases. * Tonghua Dongbao reported a **34.66% decline in total revenue in 2024**, with insulin tender repricing and channel inventory adjustment cited as major operating factors, illustrating the earnings volatility created by procurement transitions. * Gan & Lee reported a **74.83% pharmaceutical manufacturing gross margin in 2024**, indicating that portfolio mix and manufacturing economics remain critical differentiators even under procurement-led price compression. ### GLP-1 and GIP/GLP-1 Therapies Compete for Type 2 Diabetes Intensification Tirzepatide received regulatory approval for type 2 diabetes in China in **2024 (China)**, increasing treatment alternatives before insulin intensification for eligible patients. * Injectable semaglutide was approved for type 2 diabetes in China in **2021 (China)**, establishing a major GLP-1 competitor several years before the insulin forecast base year. * Greater China Ozempic sales reached approximately **USD 698 million equivalent in 2023**, illustrating commercial scale for non-insulin injectable diabetes therapies competing for eligible type 2 diabetes patients. * A domestically developed once-weekly GLP-1 therapy received market approval in **2025 (China)**, broadening local competition beyond multinational incretin products. ### High Tender Participation Intensifies Portfolio Competition The continuation procurement included **13 participating manufacturers and 53 submitted products (2024, China)**, creating intensive competition across major human-insulin and analog categories. * Lower-priced A-class products represented approximately **71% of selected products in the continuation round (2024, China)**, increasing rewards for firms capable of balancing tender price with scale economics. * Domestic products accounted for approximately **45% of hospital-reported procurement demand (2024, China)**, intensifying competition for multinational incumbents while increasing rivalry among Chinese manufacturers. * The three largest multinational insulin suppliers historically held around **70% market share before the localization shift (China)**, so current competition represents structural redistribution rather than simple market expansion. --- ## Market Opportunities ### Once-Weekly Basal Insulin Creates a New Convenience Segment China approved insulin icodec in **2025 (China)**, introducing a once-weekly basal insulin option for adults with type 2 diabetes. * The approved formulation distributes glucose-lowering activity across a **one-week dosing interval (2025, China)**, reducing injection frequency versus daily basal insulin and creating a differentiated adherence proposition. * Third-generation insulin already represented **70% of post-procurement use (China)**, indicating that clinicians and institutions can migrate toward higher-convenience analog technologies when price gaps are manageable. * A once-weekly basal product reduces routine basal injection occasions from **7 to 1 per week**, creating potential value in adherence-sensitive adult populations despite centralized procurement pressure on unit pricing. ### Domestic Substitution Expands Addressable Volume for Local Manufacturers Domestic-company products reached approximately **45% of hospital-reported procurement demand (2024, China)**, establishing a materially stronger local supply position than before national procurement. * Gan & Lee secured approximately **46.86 million units of contracted procurement volume (2024, China)**, 32.6% above its previous contracted quantity, demonstrating monetizable scale from aggressive tender participation. * Tonghua Dongbao reported total contracted procurement volume of approximately **45 million units (2024, China)**, providing a three-year volume platform for analog portfolio expansion. * Domestic products gained approximately **14 percentage points of hospital demand share versus the first procurement round**, indicating that localization is structural and can continue where product quality, manufacturing scale and tender execution converge. ### Primary-Care Diabetes Management Expands Outpatient Opportunity National policy targets at least **70% standardized primary-care management by 2030 (China)**, creating a larger managed outpatient population for chronic insulin therapy. * A target of at least **60% diabetes awareness by 2030 (China)** should increase diagnosis and treatment entry, expanding the addressable population for glucose-lowering therapy and later-stage insulin intensification. * The national plan includes **14 issuing departments (2024, China)**, increasing the probability that diabetes management improvements span insurance, primary care, digital health and public education rather than remaining isolated clinical initiatives. * Policy support explicitly extends to **digital, intelligent and portable diabetes technologies through 2030**, creating partnership opportunities around adherence support, glucose monitoring integration and pharmacy-based disease management. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview The China Insulin Market combines multinational incumbents with rapidly scaling domestic manufacturers. Centralized procurement has lowered entry barriers to hospital access while raising requirements for manufacturing scale, tender economics, product breadth and reliable national supply. * **Key players:** 10 * **New Entrants (last 5 yrs):** - ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | Novo Nordisk A/S | - | Bagsvaerd, Denmark | 1923 | Basal, rapid, premix and once-weekly insulin analogs | | Gan & Lee Pharmaceuticals Co., Ltd. | - | Beijing, China | 1998 | Domestic insulin analogs, biosimilars and insulin formulations | | Tonghua Dongbao Pharmaceutical Co., Ltd. | - | Tonghua, China | 1985 | Human insulin, basal analogs, rapid analogs and premixed insulin | | Sanofi | - | Paris, France | - | Basal and rapid insulin analogs | | Eli Lilly and Company | - | Indianapolis, United States | 1876 | Rapid, basal and premixed insulin portfolio | | The United Laboratories International Holdings Limited | - | Zhuhai, China | - | Human insulin and insulin analog formulations | | Jiangsu Wanbang Biopharmaceutical Co., Ltd. | - | Xuzhou, China | - | Human insulin and diabetes pharmaceutical products | | Yichang HEC Changjiang Pharmaceutical Co., Ltd. | - | Yichang, China | - | Human insulin and insulin analog formulations | | Hefei Tianmai Biotechnology Development Co., Ltd. | - | Hefei, China | - | Recombinant human insulin products | | Huisheng Biopharmaceutical Co., Ltd. | - | - | - | Insulin analogs and diabetes biologics | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * National VBP Contracted Volume * Analog Insulin Portfolio Breadth * China Insulin Revenue Growth * Gross Margin on Diabetes Biologics ### Analysis Covered * **Market Share Analysis:** Compares procurement volume, portfolio reach, pricing position and channel presence. * **Cross Comparison Matrix:** Benchmarks tender volume, analog breadth, revenue growth and gross margin. * **SWOT Analysis:** Assesses technology strengths, VBP exposure, pipeline risks and expansion options. * **Pricing Strategy Analysis:** Evaluates tender prices, mix shifts, affordability, rebates and margin resilience. * **Company Profiles:** Profiles portfolio scope, tender participation, headquarters, history and market focus. --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** CAGR, tender exposure, analog mix, margins, localization, pipeline * **Corporates:** contracted volume, portfolio breadth, pricing, market access, capacity * **Government:** affordability, supply security, treatment access, quality, reimbursement, localization * **Operators:** tender execution, distribution, forecasting, cold chain, hospital access, inventory * **Financial institutions:** revenue resilience, procurement concentration, cash flow, capex, margins, risk ### What You'll Gain * Market sizing and trajectory * Procurement and policy mapping * Volume and mix indicators * Segment structure and levers * Competitive landscape shortlist * CEO-grade risk priorities --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * National insulin procurement volume analysis * Manufacturer insulin revenue disclosure review * Diabetes prevalence and treatment mapping * Insulin portfolio and approval tracking #### Primary Research * Endocrinologists and diabetes center directors * Hospital pharmacy procurement manager interviews * Insulin manufacturer commercial leader interviews * Pharmaceutical distributor market access interviews #### Validation and Triangulation * 290 interviews across value chain * Tender volume against revenue checks * Patient demand against consumption checks * Pricing against procurement mix checks ### Phase 2: Market Size Estimation #### Top-Down Assessment * Diabetes population and insulin-treated patient base * Breakdown by insulin type and treatment setting * National procurement and healthcare policy indicators #### Bottom-Up Modeling * Manufacturer insulin revenue and contracted volumes * Realized insulin price and formulation benchmarks * Annual treatment volume multiplied by realized value #### Forecasting and Scenario Analysis * Patient growth, volume and analog-mix variables * VBP pricing and GLP-1 substitution scenarios * Baseline, optimistic and constrained projections through 2032 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the China insulin value chain from pharmaceutical development and manufacturing through hospital procurement, distribution, reimbursement and downstream diabetes care. * Insulin Manufacturers and Biologics Developers * Hospital Procurement and Endocrinology Providers * Pharmaceutical Distribution and Retail Channels * Payers, Policymakers and Diabetes Programs #### Sample Size Respondents were distributed across core value-chain segments to provide balanced commercial, clinical, procurement and reimbursement perspectives on the China Insulin Market. * Insulin Manufacturers and Biologics Developers - 72 respondents (Commercial Directors, Market Access Heads) * Hospital Procurement and Endocrinology Providers - 96 respondents (Endocrinologists, Pharmacy Procurement Managers) * Pharmaceutical Distribution and Retail Channels - 68 respondents (Distribution Directors, Retail Pharmacy Buyers) * Payers, Policymakers and Diabetes Programs - 54 respondents (Reimbursement Specialists, Diabetes Program Managers) #### Validation and Triangulation Validation reconciles clinical demand, manufacturer economics, institutional procurement and channel-level dispensing signals across the China insulin value chain. * Cross-segment insulin volume consistency testing * Manufacturer-to-hospital procurement volume reconciliation * Operational versus strategic respondent comparison * Price-volume-market-value arithmetic sanity testing --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: What is the size of the China Insulin Market in 2025? **A:** The China Insulin Market is **valued at USD 2,950 million in 2025**. The market is operating below its pre-procurement value peak because national volume-based procurement sharply reduced realized insulin prices, but underlying treatment demand has strengthened. Approximately 148 million Chinese adults were living with diabetes in 2024, while around 10 million patients were using insulin. As affordability improved, annual public-hospital insulin consumption increased substantially. The base-year market therefore combines lower price per unit with materially higher treatment volume and a rising share of insulin analogs. **Data used:** USD 2,950 million market value in 2025; approximately 10 million insulin users. **So what:** Investors should treat 2025 as a post-repricing normalized base rather than compare it directly with pre-procurement revenue levels. #### Q: How fast will the China Insulin Market grow through 2032? **A:** The China Insulin Market is forecast to reach **USD 3,883 million by 2032**, representing a **4.00% CAGR during 2025-2032**. Growth is expected to be led by higher treatment volumes, continued migration toward analog insulin, broader primary-care diabetes management and new long-acting formulations. Because insulin procurement remains price-disciplined, unit volumes are expected to grow faster than value. The market's upside therefore depends more on formulation mix, hospital access, manufacturing scale and patient persistence than on broad price inflation. **Data used:** USD 3,883 million forecast value in 2032; CAGR Value: 4.00%. **So what:** Suppliers need scale and differentiated formulations to outperform a market where headline value growth remains moderate. #### Q: Where is the profit pool shifting within China's insulin industry? **A:** The profit pool is shifting from high-priced legacy insulin toward analog formulations, scale-efficient domestic manufacturing and differentiated dosing technologies. Third-generation insulin usage rose from 58% before centralized procurement to 70% afterward, while domestic products increased their share of hospital procurement demand to about 45% in the 2024 continuation round. This combination favors manufacturers that can produce analog insulin at procurement-compatible economics while retaining sufficient margin through portfolio breadth, prefilled formats, basal innovation and high contracted volumes. **Data used:** 70% third-generation insulin usage; approximately 45% domestic hospital procurement demand share. **So what:** Competitive advantage increasingly comes from cost-efficient analog portfolios and tender volume rather than premium list pricing. #### Q: What is the biggest risk to the China Insulin Market forecast? **A:** The primary risks are continued procurement price pressure and substitution by non-insulin injectable therapies in type 2 diabetes. National procurement already produced an average selected-product price reduction of about 48%, with additional price tightening in the continuation round. At the same time, semaglutide, tirzepatide and additional domestic GLP-1 therapies expand physician options before insulin intensification for eligible type 2 diabetes patients. These factors can reduce realized insulin value even when the number of treated diabetes patients continues to increase. **Data used:** Approximately 48% initial procurement price reduction; tirzepatide approval in China in 2024. **So what:** Forecast resilience depends on volume growth, analog mix and differentiated insulin technology offsetting price and therapeutic substitution. #### Q: How does China compare with other major Asian insulin markets? **A:** China is the largest market among the selected Asian peers in this report. Its 2024 pharmaceutical insulin market was USD 2,837 million, versus approximately USD 1,280 million in Japan, USD 769 million in India, USD 612 million in South Korea and USD 166 million in Indonesia using publicly available directional comparators. China's growth rate is moderate relative to several peers, but its approximately 148 million adults with diabetes and nationwide procurement infrastructure create substantially greater absolute treatment and manufacturing scale. **Data used:** USD 2,837 million China market value in 2024; approximately 148 million adults with diabetes in China. **So what:** China offers greater absolute revenue and volume potential, while faster-growth peers may offer higher percentage expansion from smaller bases. #### Q: What is the most important demand driver for insulin in China? **A:** The most important demand driver is the combination of a very large diabetes population and expanding treatment access. Approximately 148 million adults in China were living with diabetes in 2024, while around 10 million patients were using insulin. Centralized procurement lowered affordability barriers and public-hospital insulin use increased from roughly 250 million annual units before procurement to about 350 million annualized units afterward. National targets to improve diabetes awareness and standardized primary-care management should further enlarge the diagnosed and consistently treated population. **Data used:** Approximately 148 million adults with diabetes in 2024; approximately 350 million annualized insulin units after procurement. **So what:** Long-term growth depends on converting diabetes prevalence into sustained diagnosis, insulin initiation and treatment persistence. #### Q: Which competitive capabilities matter most for insulin companies in China? **A:** Four capabilities are becoming decisive: national tender competitiveness, analog portfolio breadth, efficient high-volume manufacturing and differentiated formulations. The 2024 continuation procurement involved 13 manufacturers and 53 submitted products, with 49 products selected. Domestic suppliers have gained procurement share, while multinational companies retain important positions in advanced insulin technologies. Approval of once-weekly insulin icodec also raises the technology benchmark. Companies that combine competitive procurement prices with basal, rapid, premix and next-generation products are better positioned to defend margins and capture institutional volume. **Data used:** 13 participating manufacturers; 49 of 53 submitted products selected in 2024. **So what:** A narrow insulin portfolio is increasingly vulnerable because procurement and clinical innovation reward scale plus product breadth. --- ## Table of Contents # CHAPTER 14 - Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases, Market Assessment, Go-To-Market Strategy, and Survey, delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. China Insulin Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 China Insulin Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. China Insulin Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 Large Diabetes Population Sustains a Deep Treatment Pool ##### 3.1.2 National Procurement Expands Access and Institutional Reach ##### 3.1.3 National Diabetes Management Policy Broadens Diagnosis and Treatment #### 3.2 Market Challenges ##### 3.2.1 Centralized Procurement Compresses Price and Revenue Per Unit ##### 3.2.2 GLP-1 and GIP/GLP-1 Therapies Compete for Type 2 Diabetes Intensification ##### 3.2.3 High Tender Participation Intensifies Portfolio Competition #### 3.3 Market Opportunities ##### 3.3.1 Once-Weekly Basal Insulin Creates a New Convenience Segment ##### 3.3.2 Domestic Substitution Expands Addressable Volume for Local Manufacturers ##### 3.3.3 Primary-Care Diabetes Management Expands Outpatient Opportunity #### 3.4 Market Trends ##### 3.4.1 Insulin Analog Mix Expansion ##### 3.4.2 Domestic Manufacturer Share Gains ##### 3.4.3 Once-Weekly Basal Insulin Adoption ##### 3.4.4 Outpatient and Community-Care Channel Expansion #### 3.5 Government Regulation ##### 3.5.1 National Insulin Volume-Based Procurement ##### 3.5.2 Insulin Continuation Procurement Mechanism ##### 3.5.3 National Diabetes Management Targets ##### 3.5.4 Innovative Insulin Regulatory Approval ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. China Insulin Market Size #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. China Insulin Market Segmentation #### 8.1 Product Type ##### 8.1.1 Human Insulin ##### 8.1.2 Rapid-Acting Insulin Analogs ##### 8.1.3 Long-Acting and Ultra-Long Analogs ##### 8.1.4 Premixed Insulin #### 8.2 Care Setting ##### 8.2.1 Tertiary Hospitals ##### 8.2.2 Secondary Hospitals ##### 8.2.3 Primary and Community Care ##### 8.2.4 Specialist Diabetes Clinics #### 8.3 End User ##### 8.3.1 Adult Patients ##### 8.3.2 Geriatric Patients ##### 8.3.3 Pediatric and Adolescent Patients #### 8.4 Disease Area ##### 8.4.1 Type 1 Diabetes ##### 8.4.2 Type 2 Diabetes ##### 8.4.3 Gestational Diabetes ##### 8.4.4 Secondary and Other Diabetes #### 8.5 Channel ##### 8.5.1 Public Hospital Pharmacies ##### 8.5.2 Private Hospital and Clinic Pharmacies ##### 8.5.3 Retail Pharmacies ##### 8.5.4 Digital and Online Pharmacies #### 8.6 Technology ##### 8.6.1 Vial and Syringe Formulations ##### 8.6.2 Reusable Pen Cartridges ##### 8.6.3 Prefilled Disposable Pens ##### 8.6.4 Pump-Compatible Insulin Formulations #### 8.7 Geography ##### 8.7.1 East and Coastal China ##### 8.7.2 North and Northeast China ##### 8.7.3 Central and South China ##### 8.7.4 West China ### 9. China Insulin Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 National VBP Contracted Volume ##### 9.2.4 Analog Insulin Portfolio Breadth ##### 9.2.5 China Insulin Revenue Growth ##### 9.2.6 Gross Margin on Diabetes Biologics #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 Novo Nordisk A/S ##### 9.5.2 Gan & Lee Pharmaceuticals Co., Ltd. ##### 9.5.3 Tonghua Dongbao Pharmaceutical Co., Ltd. ##### 9.5.4 Sanofi ##### 9.5.5 Eli Lilly and Company ##### 9.5.6 The United Laboratories International Holdings Limited ##### 9.5.7 Jiangsu Wanbang Biopharmaceutical Co., Ltd. ##### 9.5.8 Yichang HEC Changjiang Pharmaceutical Co., Ltd. ##### 9.5.9 Hefei Tianmai Biotechnology Development Co., Ltd. ##### 9.5.10 Huisheng Biopharmaceutical Co., Ltd. ### 10. China Insulin Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 Tertiary Hospital Tender Procurement ##### 10.1.2 Secondary Hospital Formulary Selection ##### 10.1.3 Community Care Prescription Continuity ##### 10.1.4 Retail Pharmacy Refill Purchasing #### 10.2 Corporate Spend Patterns ##### 10.2.1 Hospital Insulin Budget Allocation ##### 10.2.2 Procurement Contract Volume Commitments ##### 10.2.3 Distributor Inventory Funding Cycles ##### 10.2.4 Retail Insulin Working Capital #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Price and Reimbursement Sensitivity ##### 10.3.2 Injection Frequency and Adherence ##### 10.3.3 Hypoglycemia and Treatment Complexity ##### 10.3.4 Cold-Chain and Refill Continuity #### 10.4 User Readiness for Adoption ##### 10.4.1 Analog Insulin Adoption ##### 10.4.2 Prefilled Pen Adoption ##### 10.4.3 Once-Weekly Basal Adoption ##### 10.4.4 Digital Refill and Support Adoption #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Improved Treatment Persistence ##### 10.5.2 Reduced Injection Burden ##### 10.5.3 Expanded Primary-Care Reach ##### 10.5.4 Portfolio Cross-Selling Opportunities ### 11. China Insulin Market Future Size #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Once-Weekly Basal Insulin Whitespace #### 1.2 Domestic Analog Portfolio Gaps #### 1.3 Primary-Care Access Whitespace #### 1.4 Retail and Digital Refill Opportunity ### 2. Marketing and Positioning Recommendations #### 2.1 Clinical Value Positioning #### 2.2 Tender-Economic Positioning #### 2.3 Adherence and Convenience Messaging #### 2.4 Domestic Supply Reliability Positioning ### 3. Distribution Plan #### 3.1 National Hospital Tender Coverage #### 3.2 Provincial Distributor Architecture #### 3.3 Retail Pharmacy Expansion #### 3.4 Digital Pharmacy Fulfillment ### 4. Channel and Pricing Gaps #### 4.1 Public Hospital Tender Price Gaps #### 4.2 Private Hospital Access Gaps #### 4.3 Retail Refill Price Gaps #### 4.4 Premium Technology Reimbursement Gaps ### 5. Unmet Demand and Latent Needs #### 5.1 Lower Injection Frequency #### 5.2 Improved Hypoglycemia Management #### 5.3 Community-Care Treatment Continuity #### 5.4 Affordable Analog Insulin Access ### 6. Customer Relationship #### 6.1 Endocrinologist Engagement #### 6.2 Hospital Procurement Engagement #### 6.3 Distributor Service Management #### 6.4 Patient Adherence Support ### 7. Value Proposition #### 7.1 Procurement-Compatible Economics #### 7.2 Broad Analog Portfolio #### 7.3 Reliable National Supply #### 7.4 Lower Patient Treatment Burden ### 8. Key Activities #### 8.1 Tender Preparation and Pricing #### 8.2 Hospital Formulary Access #### 8.3 Production Scale Optimization #### 8.4 Clinical Education and Adherence ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Regulatory Approval ##### 9.1.2 National Procurement Qualification ##### 9.1.3 Provincial Hospital Access ##### 9.1.4 Retail Channel Expansion #### 9.2 Export Entry Strategy ##### 9.2.1 International Insulin Registration ##### 9.2.2 Biosimilar Partner Licensing ##### 9.2.3 GMP Compliance Expansion ##### 9.2.4 Emerging-Market Distribution Partnerships ### 10. Entry Mode Assessment #### 10.1 Direct Manufacturing #### 10.2 Licensing Partnership #### 10.3 Local Commercial Partnership #### 10.4 Contract Manufacturing Model ### 11. Capital and Timeline Estimation #### 11.1 Biologics Manufacturing Investment #### 11.2 Clinical and Regulatory Investment #### 11.3 Commercial Access Investment #### 11.4 Working Capital Requirements ### 12. Control vs Risk Trade-Off #### 12.1 Tender Price Risk #### 12.2 Manufacturing Control #### 12.3 Distribution Dependence #### 12.4 Portfolio Concentration Risk ### 13. Profitability Outlook #### 13.1 Analog Mix Economics #### 13.2 Tender Volume Leverage #### 13.3 Manufacturing Scale Benefits #### 13.4 Innovation Premium Sustainability ### 14. Potential Partner List #### 14.1 National Pharmaceutical Distributors #### 14.2 Provincial Hospital Access Partners #### 14.3 Retail Pharmacy Networks #### 14.4 Digital Diabetes Management Partners ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Product Registration Completion ##### 15.2.2 Procurement and Formulary Access ##### 15.2.3 Provincial Distribution Expansion ##### 15.2.4 Portfolio and Capacity Scaling ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage - Priority Metros and Tier 2/3 Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework (50 In-Depth Interviews) ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design (200 Structured Surveys) ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1 - Insulin Manufacturers and Biologics Developers ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample Size and Metro Distribution #### 3.2 Cohort 2 - Hospital Procurement and Endocrinology Providers ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample Size and City Distribution #### 3.3 Cohort 3 - Pharmaceutical Distribution and Retail Channels ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample Size and Tier 2/3 City Distribution #### 3.4 Cohort 4 - Payers, Policymakers and Diabetes Programs ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Procurement and Compliance Drivers ##### 3.4.4 Represented Sample Size and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 Diabetes Population and Diagnosis Linkages ##### 4.1.2 Primary-Care Expansion Impact ##### 4.1.3 Procurement Cycles and Purchasing Timing ##### 4.1.4 Import and Domestic Supply Dependency #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Frequency and Volume of Insulin Use ##### 4.2.2 Treatment Intensification Patterns ##### 4.2.3 Brand Loyalty vs Price Sensitivity Trade-Off ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Cohorts ##### 4.3.2 Price Benchmarking Against Alternative Insulins ##### 4.3.3 Procurement Pricing Disparities ##### 4.3.4 Total Treatment Cost Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Biologic Quality Standards ##### 4.4.2 Safety and Regulatory Compliance Awareness ##### 4.4.3 Domestic vs Imported Insulin Perception ##### 4.4.4 Supply Reliability Expectations #### 4.5 Cultural, Regional, and Contextual Demand Factors ##### 4.5.1 Regional Hospital Demand Hotspots ##### 4.5.2 Physician Prescribing Norms ##### 4.5.3 Clinical Guideline Influence ##### 4.5.4 Digital Diabetes Management Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Medical Congress and Clinical Education Impact ##### 4.6.2 Role of Digital Patient Education ##### 4.6.3 Distributor and Pharmacy Influence ##### 4.6.4 Hospital Formulary Partnership Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Gaps Between Insulin Supply and Patient Expectations #### 5.2 Latent Demand in Underpenetrated Treatment Cohorts #### 5.3 Willingness to Adopt New Insulin Technologies #### 5.4 Pain Points Surfaced Across Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Customer Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us